Audit: QRS - Medium-Chain Triglycerides for Health & Longevity

Audit conducted on 26/08/2026 06:55 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect figures, benefit/risk tiers, contraindications, interactions, biomarker rows and qualitative markers trace to ER Therapeutic Protocol, Practical Considerations, Discontinuation & Cycling, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“no controlled data exist beyond six months” (time_1_sub) mirrors ER line 353; “unproven inflammatory claim” (marker_9_why) mirrors ER line 423.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications; “midlife is untested” preserves the ER’s negative finding rather than implying benefit.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list; Key Interactions from the ER’s interaction bullets; no modifying factor is promoted into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT numbers, expert names or product brands appear; the named drugs (canagliflozin, empagliflozin, dapagliflozin, glipizide, glimepiride, topiramate, zonisamide, acetazolamide, orlistat, psyllium, acacia) all appear in ER lines 277–291.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified doses, ranges and biomarker targets presented without hedging or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Evening dosing was tested in the frailty trials”), not directive.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; monitoring cadence is stated as noun phrases rather than instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, or “should”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are the necessary ER-sourced entity names (drug classes, biomarkers); no gratuitous jargon.
2.8	Information is presented in a concise and very compact manner	🟢	Sub-lines are one to two short sentences; gate items are bare noun phrases.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no “you”/”your” in the source.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range biomarker targets and titration detail address exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, fasted-morning timing and capillary ketone testing presume effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes willingness to test ketones and re-run lipid panels.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance flags that midlife is untested and that added-not-swapped intake is simply extra calories — the two points that matter most for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal intolerance”, “hepatic strain”, “sodium-glucose cotransporter-2 inhibitors” used in the body; plain-language wording is confined to At-A-Glance, where item 7.4 requires it.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Line-by-line diff against [qrs_template] shows every fixed heading, gate heading, tier label and column header byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	73 unique data-qrs-var spans present = 34 fixed template vars + 33 marker vars (11 rows × 3) + 6 qualitative vars; all opening/closing span tags balanced (76/76).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three <span website="..."> elements and all CSS/structure are unchanged; the diff contains only variable substitutions.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard maintenance dose”, action_2_label “Best time of day”, action_3_label “Split versus single dosing” are the ER’s bold labels verbatim (ER lines 322, 332, 336).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels are verbatim; monitoring row labels are the ER biomarker table’s own names; qualitative items are the ER’s own bullets.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s “⚠️ Conflicted” markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Per-section budgets respected: At-A-Glance 58 words, three protocol and three time cells, one-line tier entries, bare-phrase gate items, and single-clause monitoring “Why” cells.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed elsewhere except the legitimately rendered date and model name.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: medium_chain_triglycerides_2026-0826-0505_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0826-0635.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Medium-Chain Triglycerides for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Medium-Chain Triglycerides for Health & Longevity”, matching ER frontmatter line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/26/2026” from qrs_creation_date: 2026-0826-0635.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses both ER Conclusion paragraphs (lines 454–456): mechanism, where benefit sits, tolerability, lipid dependence, and the substitution requirement.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 454–456: burns fast into ketones; small thinking-score gains where memory is slipping; strength gains in the very frail; midlife untested; loose stools fade with slow escalation; butter vs olive oil; added = extra calories.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “ketones” is immediately glossed as “fuel for brain and muscle”, and “thinking-score”, “loose stools”, “blood fats” replace clinical register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial is named or dated.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only qualitative magnitude (“small”) appears; no numbers.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from the “Populations who should avoid Medium-Chain Triglycerides” list, ER lines 293–300.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER exclusion bullets are present, one-to-one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the span (lines 572–582).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses stripped: “(severe liver failure)” and “given absent human safety data” removed; no dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(Child-Pugh Class C)” staging, “>500 mg/dL” threshold, “the first three months after an episode” time window and “at supplemental doses above culinary amounts” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation; the single “>” is a numeric threshold (fasting triglycerides >500 mg/dL).
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies six such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from ER lines 277–291.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets present; none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements (lines 590–599).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity words, mechanisms and every “Mitigation:” clause are stripped; only the agent or exposure name remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved for all four bullets that carry them: SGLT2 inhibitors, insulin/sulfonylureas, carbonic anhydrase inhibitors, and soluble fiber.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation appears in the ER interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol lines 322–348.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and dose-splitting — the three decisions a reader must make before starting.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies fourteen protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“15–30 g daily” (ER 322), “Fasted morning” (ER 332), “2–3 divided doses” (ER 336), with sub-lines drawn from ER 322, 324, 342, 332 and 336.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cognition, muscle strength and blood ketones — the three horizons the ER names at line 383.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Cognitive performance and muscle strength are the ER’s first two High-tier benefits, in ER order; the ketone reading, a mechanism marker rather than a benefit, is placed last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“1–6 months” and “12 weeks” from ER 383; “30–120 minutes” from ER 383 with decay from ER 334; regression-after-stopping sub from ER 361; six-month data limit from ER 353.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet (line 383).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All seven ER benefit sub-headings are represented in their ER tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 545–562).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Entries are the ER sub-headings alone; no magnitude figures or funding caveats carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit entry; the ER’s “⚠️ Conflicted” marker on Insulin Sensitivity is dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four benefit tiers.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven ER risk sub-headings are represented in their ER tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 611–625).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Entries are the ER sub-headings alone; no incidence thresholds or mmol/L figures carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk entry; the “⚠️ Conflicted” marker on Adverse Blood Lipid Shifts is dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four risk tiers.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Every row is taken from the ER biomarker table at lines 413–425.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER biomarkers present: fasting triglycerides, ApoB, LDL, HDL, fasting insulin/HOMA-IR, HbA1c, capillary beta-hydroxybutyrate, ALT, hs-CRP, body composition, grip strength.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 794: ketone check at 90 minutes in week one, lipid/metabolic panel at 8–12 weeks then every 6–12 months, body composition and grip strength at 12 weeks then annually — matching ER line 411.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the “Qualitative markers worth tracking” list, ER lines 429–434.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, in ER order and wording.

Issues 26/08/2026 06:55

Pass rate 100.00%. No issues found.

Issues 26/08/2026 06:49

1. 10.4 — Protocol cell sourced from Risk Mitigation: action_1_sub ends with “Escalation typically begins at 5 mL, rising weekly”, lifted from the ER Risk Mitigation Strategies bullet at line 305 rather than the ER Therapeutic Protocol section, whose own titration statement is “adults over 75 generally start at 2.5–5 mL” (line 342).
2. 2.8 — Time-to-effect sub-lines restate values: time_1_sub (“Cognitive trials ran 1–6 months before differences emerged”) and time_2_sub (“Muscle trials ran 12 weeks before differences emerged”) repeat their own value cells “1–6 months” and “12 weeks” verbatim, consuming one-page budget without adding information.

Fixes 26/08/2026 06:49

1. 10.4 — Protocol cell sourced from Risk Mitigation: Replaced the closing sentence of action_1_sub, “Escalation typically begins at 5 mL, rising weekly” (from the ER Risk Mitigation Strategies section), with “Adults over 75 generally start at 2.5–5 mL”, taken from the ER Therapeutic Protocol section.
2. 2.8 — Time-to-effect sub-lines restate values: Rewrote time_1_sub to “Functional endpoints lag far behind the ketone rise, and no controlled data exist beyond six months” and time_2_sub to “Gains regressed toward baseline within six weeks of stopping, so they depend on continued intake”, so neither sub-line repeats its own value cell.

Issues 26/08/2026 06:43

1. 2.4 / 2.5 / 2.6 / 2.9 — Imperative dosing instruction: [action_1_sub] closes with “Start at 5 mL and titrate weekly.” — an imperative that addresses the reader directly and reads as clinical guidance rather than presented evidence; the ER carries this only as a bold strategy label, not as a directive in running prose.

Fixes 26/08/2026 06:43

1. 2.4 / 2.5 / 2.6 / 2.9 — Imperative dosing instruction removed: In [action_1_sub], “Start at 5 mL and titrate weekly.” was rewritten to “Escalation typically begins at 5 mL, rising weekly.”, replacing the reader-directed imperative with a descriptive statement of the ER’s titration strategy.